Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-248 plus orelabrutinib in treatment-naïve CLL/SLL (Phase II/III, China)
CTR20240960Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mesutoclax, orelabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Innovent Biologics. Started May 2024; status: active.
02
Drugs
mesutoclaxorelabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20240960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240960.